Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation.

Todd JL, Kelly FL, Nagler A, Banner K, Pavlisko EN, Belperio JA, Brass D, Weigt SS, Palmer SM.

Am J Transplant. 2019 Oct 30. doi: 10.1111/ajt.15667. [Epub ahead of print]

PMID:
31665560
2.

Evidence of region-wide bat population decline from long-term monitoring and Bayesian occupancy models with empirically informed priors.

Rodhouse TJ, Rodriguez RM, Banner KM, Ormsbee PC, Barnett J, Irvine KM.

Ecol Evol. 2019 Sep 11;9(19):11078-11088. doi: 10.1002/ece3.5612. eCollection 2019 Oct.

3.

Improving geographically extensive acoustic survey designs for modeling species occurrence with imperfect detection and misidentification.

Banner KM, Irvine KM, Rodhouse TJ, Wright WJ, Rodriguez RM, Litt AR.

Ecol Evol. 2018 May 20;8(12):6144-6156. doi: 10.1002/ece3.4162. eCollection 2018 Jun.

4.

'Just a GP': a mixed method study of undermining of general practice as a career choice in the UK.

Alberti H, Banner K, Collingwood H, Merritt K.

BMJ Open. 2017 Nov 3;7(11):e018520. doi: 10.1136/bmjopen-2017-018520.

5.

Considerations for assessing model averaging of regression coefficients.

Banner KM, Higgs MD.

Ecol Appl. 2017 Jan;27(1):78-93. doi: 10.1002/eap.1419. Epub 2016 Nov 22.

PMID:
27874997
6.

Pathogen prevalence and abundance in honey bee colonies involved in almond pollination.

Cavigli I, Daughenbaugh KF, Martin M, Lerch M, Banner K, Garcia E, Brutscher LM, Flenniken ML.

Apidologie. 2016;47:251-266. Epub 2015 Oct 21.

7.

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP.

Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25.

PMID:
24429275
8.

TRP channels: emerging targets for respiratory disease.

Banner KH, Igney F, Poll C.

Pharmacol Ther. 2011 Jun;130(3):371-84. doi: 10.1016/j.pharmthera.2011.03.005. Epub 2011 Mar 21. Review.

PMID:
21420429
9.

Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.

Growcott EJ, Coulthard A, Amison R, Hardaker EL, Saxena V, Malt L, Jones P, Grevot A, Poll C, Osborne C, Banner KH.

J Cyst Fibros. 2011 May;10(3):166-74. doi: 10.1016/j.jcf.2010.12.007. Epub 2011 Jan 17.

10.

Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

Hardaker EL, Freeman MS, Dale N, Bahra P, Raza F, Banner KH, Poll C.

Br J Pharmacol. 2010 Aug;160(8):1985-96. doi: 10.1111/j.1476-5381.2010.00857.x.

11.

Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Banner KH, Press NJ.

Br J Pharmacol. 2009 Jul;157(6):892-906. doi: 10.1111/j.1476-5381.2009.00170.x. Epub 2009 Jun 5. Review.

12.

PDE4 inhibitors - a review of the current field.

Press NJ, Banner KH.

Prog Med Chem. 2009;47:37-74. doi: 10.1016/S0079-6468(08)00202-6. Review. No abstract available.

PMID:
19328289
13.

Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.

Banner KH, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, Moss R, Poll C, Randell SH, Rossi AG, Thomas L, Waltz D.

J Cyst Fibros. 2009 Jan;8(1):1-8. doi: 10.1016/j.jcf.2008.10.002. Epub 2008 Nov 20. Review.

14.

Your strategies for improving patient registration processes.

Banner K, Hardin P, Johnson J, Murphy JP, Sornberger L.

Healthc Financ Manage. 2008 Jul;62(7):suppl 1-4. No abstract available.

PMID:
18683412
15.

An unusual cause of duodenal obstruction.

Banner K, Helft S, Kaushik N.

Gastrointest Endosc. 2008 Nov;68(5):1002-3; discussion 1003. doi: 10.1016/j.gie.2008.03.1090. Epub 2008 Jun 18. No abstract available.

PMID:
18565524
16.

An unusual cause of dysphagia in a young woman: esophageal duplication cyst.

Banner K, Helft S, Kadam J, Miah A, Kaushik N.

Gastrointest Endosc. 2008 Oct;68(4):793-5. doi: 10.1016/j.gie.2008.02.004. Epub 2008 Jun 2. No abstract available.

PMID:
18513721
17.

Animal models of cough: literature review and presentation of a novel cigarette smoke-enhanced cough model in the guinea-pig.

Lewis CA, Ambrose C, Banner K, Battram C, Butler K, Giddings J, Mok J, Nasra J, Winny C, Poll C.

Pulm Pharmacol Ther. 2007;20(4):325-33. Epub 2006 Dec 13.

PMID:
17240178
18.

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.

Respir Res. 2006 Jan 19;7:9.

19.

Hypoxia amplifies the proliferative capacity of distal human pulmonary artery smooth-muscle cells.

Growcott EJ, Banner KH, Wharton J.

Chest. 2005 Dec;128(6 Suppl):600S-601S. No abstract available.

PMID:
16373856
20.

Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.

Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD.

Br J Pharmacol. 2004 Nov;143(5):590-8. Epub 2004 Oct 4.

21.

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

Banner KH, Trevethick MA.

Trends Pharmacol Sci. 2004 Aug;25(8):430-6. Review.

PMID:
15276712
22.

Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.

Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M.

Pulm Pharmacol Ther. 2003;16(2):97-104. Review.

PMID:
12670778
23.

Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.

Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A, O'Connor BJ, Spina D, Page CP.

Br J Pharmacol. 2001 Jul;133(5):722-9.

24.

Evidence to suggest that the phosphodiesterase 4 isoenzyme is present and involved in the proliferation of umbilical cord blood mononuclear cells.

Banner KH, Dimitriou G, Kinali M, Page CP, Greenough A.

Clin Exp Allergy. 2000 May;30(5):706-12.

PMID:
10792363
25.

Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells.

Banner KH, Hoult JR, Taylor MN, Landells LJ, Page CP.

Biochem Pharmacol. 1999 Nov 1;58(9):1487-95.

PMID:
10513992
26.
27.

The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP.

Br J Pharmacol. 1996 Nov;119(6):1255-61.

29.

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors.

Banner KH, Page CP.

Clin Exp Allergy. 1996 Mar;26 Suppl 2:2-9. Review. No abstract available.

PMID:
8963872
30.

Effect of isoenzyme selective phosphodiesterase inhibitors on the proliferation of murine thymus and spleen cells.

Banner KH, Bertin B, Moodley I, Page CP.

Pulm Pharmacol. 1996 Feb;9(1):35-41.

PMID:
8843508
32.

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors.

Banner KH, Page CP.

Monaldi Arch Chest Dis. 1995 Aug;50(4):286-92. Review.

PMID:
7550209
33.
34.

The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways.

Banner KH, Marchini F, Buschi A, Moriggi E, Semeraro C, Page CP.

Pulm Pharmacol. 1995 Feb;8(1):37-42.

PMID:
8535097

Supplemental Content

Loading ...
Support Center